Day: February 25, 2021

Los Angeles, CA, Feb. 25, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer‎, announced today that the CEO of the Company, Cameron Chell, will speak on the Sustainability/Rethinking Impact 2021 panel hosted by Canaccord Genuity.The virtual event takes place on March 4, 2021 at 10AM PST/1PM EST. Cameron Chell will join a panel to discuss: Rethinking Autonomy and the Drone Economy moderated by Ken Herbert, Managing Director, Canaccord Genuity Equity Research. The panel will focus on drones and their disruptive potential in the package delivery and logistics markets,“I am honored to be part of Canaccord’s inaugural Global Sustainability Event,” said Cameron Chell, CEO of Draganfly. “Canaccord has put together...

Company progresses from LOI to MIPA3 to acquire cultivation and production licenses and to begin cultivation on proprietary landLas Vegas, NV, Feb. 25, 2021 (GLOBE NEWSWIRE) — MJ Holdings, Inc. (OTC Pink: MJNE) a diversified holding company, which through its subsidiaries, provides services to the regulated cannabis industry inclusive of cultivation and production management, infrastructure development and sales is pleased to inform shareholders that it has progressed from a Letter of Intent (LOI) to a Membership Interest Purchase Agreement (MIPA3) to purchase two cultivation licenses (medical and recreational) and two production licenses (medical and recreational) and transfer the appropriate licenses to proprietary land.The MIPA3 with MJ Distributing, Inc. and affiliates (not related to MJ Holdings, Inc) provides for a closing...

A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye.Elevated VEGF is associated with choroidal neovascularisation (CNV), the cause of wet AMD. Recent data from a laser-induced CNV model suggests one dose of long-acting PASylated nomacopan (PAS-nomacopan) reduced neo-vascularisation by the same amount as Eyelea®, a U.S. Food and Drug Administration (FDA)-approved treatment for AMD.The combined impact of bifunctional nomacopan, which inhibits LTB4, and thereby VEGF production, and also inhibits complement C5, may provide a unique modality for treatment of a number of serious eye diseases, including uveitis and both dry and wet AMD.NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) — Akari Therapeutics,...

OMER, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced the pricing of an underwritten public offering of 3,258,438 American Depositary Shares (the “ADSs”). Each ADS is being sold to the public at a price per ADS of $2.60. The gross proceeds to the Company from this offering are expected to be approximately $8.5 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is expected to close on or about March 1, 2021, subject to customary closing conditions.The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.In addition, the Company has granted the underwriter...

Meddelelse nr. 3 – 2021til Nasdaq Copenhagen   2021.02.25Årsrapport 2020 – rekordresultat og indstilling om øget udbytteFor Brødrene A & O Johansen A/S og koncernen (AO) har året 2020 været præget af en højere salgsvækst end forventet.Størstedelen af 2020 har været påvirket af COVID-19. I perioder med delvis nedlukning af mange dele af samfundet har kunderne efterspurgt fleksibilitet ved valg af salgsplatforme og handelsform. AO har som omnichannel-virksomhed kunnet tilbyde dette.Omsætningen i 2020 udgjorde 4.098,3 mio. kr., svarende til en salgsvækst på 14,4 %. Salget fordeltes med 3.502,4 mio. kr. fra det professionelle marked (B2B) og 595,9 mio. kr. fra privatmarkedet (B2C). Væksten i det professionelle marked udgjorde 11,6 %, mens væksten i det private marked udgjorde 34,4 %. For så vidt angår væksten i det private marked, kan...

Siili Solutions Oyj Pörssitiedote 25.2.2021 kello 16.00Siili Solutions Oyj – Johdon liiketoimet – Malviniemi____________________________________________IlmoitusvelvollinenNimi: Malviniemi, JarkkoAsema: Muu ylin johtoLiikkeeseenlaskija: Siili Solutions OyjLEI: 7437003WYXJUSV27Q316Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 7437003WYXJUSV27Q316_20210224142052_29____________________________________________Liiketoimen päivämäärä: 2021-02-23Kauppapaikka: XHELInstrumentti tyyppi: OSAKEISIN: FI4000043435Liiketoimen luonne: HANKINTALiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 94 Yksikköhinta: 15.9784 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 94 Keskihinta: 15.9784 EURLisätietoja:Johtaja, lakiasiat ja sijoittajasuhteetPuhelin: 045 635 7416, sähköposti: hanna.seppanen(at)siili.comJakelu:Nasdaq Helsinki OyKeskeiset...